Hemcheck Sweden AB: Presents results from user tests at Karlstad Central Hospital
21.6.2017 09:00 | NASDAQ OMX
Hemcheck Sweden AB (publ) presents results from user tests at Karlstad Central Hospital
hemCheck, a medical technology company addressing the issue of hemolysis, announces results from user tests at Karlstad Central Hospital, where nurses used a prototype of hemCheck's point of care test in a clinical setting. The user tests confirmed that hemolysis is a significant problem for the emergency department, showed that the prototype is user friendly and that the rate of hemolysis for Troponin T tests could be lowered by 75% when using this prototype.
hemCheck carried out user tests of a prototype of its point of care hemolysis detection test, Helge, in the emergency department at Karlstad Central Hospital during December 2016 to May 2017. The purpose of the trial was to gain a better understanding of user friendliness and test performance in a clinical setting, in order to identify improvement areas for the upgraded product version, including a digital reader, which is being developed for evaluation and testing.
The Helge prototype was considered user friendly and was easily incorporated in the clinical setting. Using the current prototype (set for hemolysis index (HI) cutoff 50), lowered the hemolysis rate for Troponin T tests (HI cutoff 100) by 75%, and the hemolysis rate for Potassium, ALAT, ALP tests by 36% (HI cutoff 50). Adjustments to the prototype, including the use of a digital reader, are being made to improve performance accuracy for hemolysis sensitive analyses, such as Potassium, ALAT, ALP.
hemCheck CEO Annelie Brolinson comments:
- These user tests have clearly confirmed the relevance of hemolysis and align well with published clinical findings. With a prototype in the development phase, we are very proud to receive such a positive response among users, and that indicates that we are on the right track with our unique point of care test. With this knowledge, we now continue our work of enhancing the product concept's ability to identify hemolyzed blood samples, thereby improving patient safety and patient flows within the health care system.
hemCheck Sweden AB (publ) is developing and commercializing a unique product concept, Helge, that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples being ruled unfit for analysis. This can lead to lower quality healthcare, increased risks for patients and higher costs. By instantly detecting hemolysis in blood tests, Helge can contribute to improved care for patients throughout the world. hemCheck is headquartered in Karlstad, Sweden.
hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
651 88 Karlstad
This is information which hemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person's auspices, for publication on June 21, 2017, at 09:00.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hemcheck Sweden AB via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30 | Pressmeddelande
IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017. A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti
TGS Q2 2017 webcast and teleconference27.7.2017 18:14 | Pressmeddelande
ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-
Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36 | Pressmeddelande
VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850 VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after
Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22 | Pressmeddelande
Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00 | Pressmeddelande
- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia - TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum